SPRC:NASDAQ, SciSparc Ltd.
Why SPRC stock fell on October 27
SciSparc Ltd. fell 34.1%
on Tuesday, October 27, 2026, on 1,940,000 shares.
The headline around the move:
SPRC stock overview
SciSparc Ltd. (SPRC:NASDAQ) closed at $0.598 on November 2, 2026,
down 11.64% on the day.
The stock trades 98.0% below its 52-week high of $30.63
and 8.7% above its 52-week low of $0.550.
Over the past year, it lost 97.8%.
SciSparc Ltd. is part of the Health Care sector.
Key figures
- Price
- $0.598
- Day change
- -11.64%
- Volume
- 225,040
- Average volume
- 1,344,179
- Market cap
- 347K+
- 52-week range
- $0.550 – $30.63
- 50-day average
- $4.17
- 200-day average
- $5.59
Price action over the past year
In 252 trading sessions since October 31, 2025, SPRC closed higher on 92 days (37%).
Its best day was May 28, 2026 (+140.32%) and its worst was October 15, 2026 (-44.90%).
The stock moved 10% or more in a single session 39 times.
It opened at least 5% above the previous day's high 8 times.
Recent signals
SPRC news
-
Oct 26, 2026:
BC-Most Active Stocks
-
Oct 22, 2026:
NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
-
Oct 22, 2026:
SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome
-
Oct 19, 2026:
SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications
-
Oct 15, 2026:
SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies
-
Oct 7, 2026:
SciSparc: Subsidiary NeuroThera Labs' CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company's Quantum Architecture
-
Sep 23, 2026:
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
-
Sep 2, 2026:
SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
About SciSparc Ltd.
SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company operates in the single segment of the Development of drugs based on cannabinoid molecules to be approved by an official regulatory authority.
Similar stocks
Find more stocks like SPRC with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.